BioCardia (NASDAQ: BCDA) CEO adds 5,000 shares at $1.11

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,000 shares of the company’s Common Stock at $1.11 per share on April 29, 2026.

Following this transaction, he directly owns 280,766 shares of BioCardia common stock.

Insider Trade Summary

Net Buyer: 5,000 shares ($5,550)

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,000 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$1.11	$6K

Holdings After Transaction: Common Stock — 280,766 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 5,000 shares Purchase price: $1.11 per share Post-transaction holdings: 280,766 shares +1 more

4 metrics

Shares purchased 5,000 shares Open-market purchase of Common Stock

Purchase price $1.11 per share Price paid for BioCardia Common Stock

Post-transaction holdings 280,766 shares Directly owned Common Stock after transaction

Net buy/sell shares 5,000 shares transactionSummary netBuySellShares (net-buy)

Key Terms

open-market purchase, Common Stock, non-derivative, transaction code P

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type": "non-derivative""

transaction code P financial

"transaction_code": "P""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		P		5,000	A	$1.11	280,766	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David McClung, by power of attorney	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioCardia (BCDA) report on this Form 4?

BioCardia reported that President and CEO Peter Altman made an open-market purchase of company Common Stock. He bought 5,000 shares at $1.11 per share, increasing his directly held position as disclosed in the filing.

How many BioCardia (BCDA) shares did the CEO buy and at what price?

Peter Altman purchased 5,000 shares of BioCardia Common Stock at a price of $1.11 per share. The transaction was classified as an open-market or private purchase under transaction code P on the Form 4.

What are Peter Altman’s BioCardia (BCDA) holdings after this transaction?

After the reported transaction, Peter Altman directly owns 280,766 shares of BioCardia Common Stock. This total reflects his position immediately following the purchase of 5,000 shares disclosed in the Form 4 filing.

How is the BioCardia (BCDA) CEO’s trade classified on the Form 4?

The CEO’s trade is classified as a non-derivative transaction in Common Stock, using transaction code P. The filing describes it as a “Purchase in open market or private transaction,” indicating a straightforward share acquisition rather than an option exercise or derivative event.

Does the BioCardia (BCDA) Form 4 show net buying or selling activity?

The Form 4 shows net buying activity. The transactionSummary reports one buy transaction totaling 5,000 shares and no sales, resulting in netBuySellShares of 5,000 and a net-buy direction for the reporting period covered.